Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP BRAIN: Sacituzumab tirumotecan plus bevacizumab in EGFR-mutant NSCLC with brain metastases after 3rd-generation EGFR-TKI
ChiCTR2500111474Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and bevacizumab in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Intracranial objective response rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecanbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR2500111474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111474.